---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-097764"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:21:31.931572+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify

## Summary
- All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.
- Control arm (transplant alone) had 2 relapses at ~6 months and 1 death; only 1 of 8 achieved complete donor chimerism.
- Solid tumor: >40 patients screened; ~60% qualify for at least one TCR-T, ~30% eligible for multiplex (T-Plex) therapy.
- First 3 solid tumor patients expected to be dosed early May 2024; initial data from singleplex and multiplex cohorts in H2 2024.
- Heme: expansion cohorts at Phase 2 dose planned Q3 2024; Phase 1 enrollment completion and 1-year data in H2 2024.

## SEC filing metadata
- accession: 0001193125-24-097764
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/0001193125-24-097764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/d820546d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-097764
- JSON: https://secwatch.observer/filing/0001193125-24-097764.json
- Plain text: https://secwatch.observer/filing/0001193125-24-097764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.